Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | HPN | P05981 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26503484 | 0.85 | MAPK1 (0.64) | MAPK1LMNAPOLBMEN1KMT2A | |
| SCHEMBL26456739 | 0.84 | CA1 (0.45) | PKMFPR2POLBRECQLMEN1 | |
| SCHEMBL7230992 | 0.83 | KDM4E (0.51) | PKMFPR2POLBRECQLMEN1 | |
| SCHEMBL26502102 | 0.82 | MAPK1 (0.43) | MAPK1PKMFPR2LMNAPOLB | |
| SCHEMBL14354732 | 0.81 | GAA (0.56) | MAPK1PKMPOLBCA1CA2 | |
| SCHEMBL12407115 | 0.77 | PKM (0.52) | MAPK1PKMFPR2LMNAPOLB | |
| SCHEMBL7231047 | 0.77 | MEN1 (0.42) | PKMLMNAPOLBRECQLMEN1 | |
| SCHEMBL22583742 | 0.76 | HDAC1 (0.49) | MAPK1PKMLMNAPOLBMEN1 | |
| SCHEMBL11436787 | 0.74 | SMN1; SMN2 (0.50) | PKMLMNARECQLMEN1KMT2A | |
| SCHEMBL26503435 | 0.74 | MAPT (0.61) | LMNAPOLBCA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321123-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321123-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB | SERPINB1, LTA, TFPI | MAPK1 1005/4885PKM 3942/4885FPR2 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.